Vir Biotechnology, Inc. (VIR)
| Previous close | 7.33 |
| Open | 7.24 |
| Bid | 7.29 x 100 |
| Ask | 7.35 x 100 |
| Day's range | 7.20 - 7.44 |
| 52-week range | 7.12 - 13.09 |
| Volume | |
| Avg. volume | 793,068 |
| Market cap | 997.472M |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.58 |
| Earnings date | 31 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.86 |
Simply Wall St.Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company
Key Insights Significantly high institutional ownership implies Vir Biotechnology's stock price is sensitive to their...
Business WireVir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
SAN FRANCISCO, October 03, 2024--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.
Business WireVir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
SAN FRANCISCO, September 10, 2024--Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne will join the Vir Executive Management Team and report directly to the company’s Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA.
